EARNEST Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

EARNEST Partners’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2	Closed	–	–	1240
2018 Q1	$0	Hold	2	–	–	﹤0.01%	1217
2017 Q4	$0	Buy	+2	New	+$126	﹤0.01%	1215
2017 Q1	–	Sell	-2	Closed	–	–	972
2016 Q4	$0	Buy	+2	New	+$238	﹤0.01%	1176

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

EARNEST Partners's ICPT Position: Q2 2018 in Review

EARNEST Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2018, closing a stake of 2 shares.

EARNEST Partners first reported a position in ICPT in Q4 2016 and held it in 3 quarters. The position peaked at $0 in Q1 2018. 163 funds tracked by Wall St. Rank hold ICPT as of Q2 2018.

EARNEST Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
EARNEST Partners sold 2 Intercept Pharmaceuticals, Inc. shares in Q2 2018.
EARNEST Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2016 and held it in 3 quarters.
EARNEST Partners's Intercept Pharmaceuticals, Inc. position peaked at $0 in Q1 2018.
163 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2018.

Based on EARNEST Partners's 13F filing for Q2 2018, filed 13 Aug 2018.